吉西他滨联合顺铂治疗复发或难治性非霍奇金淋巴瘤

目的评价吉西他滨联合顺铂治疗复发或难治性非霍奇金淋巴瘤的疗效和安全性。方法31例复发或难治性淋巴瘤接受吉西他滨联合顺铂方案化疗：吉西他滨1000mg／m^2第1天和第8天，顺铂25mg／m^2第1～3天，21d为1个周期。结果31例患者中完全缓解4例，部分缓解13例，有效率54．8％。肿瘤中位进展（TTP）时间4．5个月，1年生存率32．3％。毒性反应主要为血液学毒性和恶心呕吐反应。结论吉西他滨联合顺铂方案是治疗复发或难治性非霍奇金淋巴瘤安全、有效的化疗方案。

Gemcitabine plus cisplatin in the treatment of 31 relapsed or refractory non-Hodgkin' s lymphoma

Objective To evaluate the efficacy and safety of a combination of gemcitabine plus cisplatin in patients with relapsed or refractory non-Hodgkin＇s lymphoma. Methods 31 patients with relapsed or refractory non-Hodgkin＇ s lymphoma were treated by gemcitabine 1000mg/m^2 on D1,D8 and cisplatin 25mg/m^2 on D1-3. Cycles were repeated every 21 days. Ressults Of 31 assessable patients, an overall response rate of 54.8% was observed, including 4 complete response and 13 partial response. Median time to progression was 4.5 months, and 1-year survival rate was 32.3%. Toxicity mainly included myleosuppression, nausea/vomiting. Conclusions Gemcitabine plus cisplatin chemotherpy regimen is safe and effective for patients with relapsed or refractory non-Hodgkin＇s lymphoma.